期刊
FRONTIERS IN PHARMACOLOGY
卷 12, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2021.661173
关键词
hybrid molecules; lung cancer; anticancer; structure-activity relationship; triazole
资金
- National Natural Science Foundation of China [81371601]
- Natural Science Foundation of Shandong Province [ZR2019MH019, ZR2019BA015]
- Science & Technology Department of Sichuan Province [2019YJ0674]
Recent advances in research on 1,2,3-triazole-containing compounds with anti-lung cancer potential have been significant, with discussions on their structure-activity relationship and mechanisms of action to facilitate the rational development of novel anti-lung cancer candidates.
Lung cancer is the most common malignancy and leads to around one-quarter of all cancer deaths. Great advances have been achieved in the treatment of lung cancer with novel anticancer agents and improved technology. However, morbidity and mortality rates remain extremely high, calling for an urgent need to develop novel anti-lung cancer agents. 1,2,3-Triazole could be readily interact with diverse enzymes and receptors in organisms through weak interaction. 1,2,3-Triazole can not only be acted as a linker to tether different pharmacophores but also serve as a pharmacophore. This review aims to summarize the recent advances in 1,2,3-triazole-containing compounds with anti-lung cancer potential, and their structure-activity relationship (SAR) together with mechanisms of action is also discussed to pave the way for the further rational development of novel anti-lung cancer candidates.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据